Securities Times reporter Wu Jiaming
At present, biomedicine has been included in one of the national key development projects, and Shenzhen is also vigorously promoting the development of biomedicine and other industries.
On July 26, the Shenzhen Development and Reform Commission officially issued "Several Measures for Shenzhen to Promote the High-quality Development of Biomedical Industry Clusters", "Several Measures for Shenzhen to Promote the High-quality Development of High-end Medical Device Industry Clusters", and "Shenzhen to Promote the Big Health Industry". "Several Measures for High-Quality Development of Clusters" and other three policy measures to support Shenzhen's biopharmaceutical industry to become bigger and stronger.
It is reported that the "Several Measures for Shenzhen to Promote the High-Quality Development of Biopharmaceutical Industry Clusters" issued this time will specifically speed up the construction of pharmaceutical industry infrastructure, strengthen the transformation capacity of drug clinical research, accelerate the process of drug registration and approval, and strive to create biopharmaceutical characteristics. Parks, increase support for R&D and production of pharmaceutical companies, etc.
Among them, in terms of accelerating the construction of pharmaceutical industry infrastructure, support the construction of state-level innovation carriers such as state key laboratories and national engineering research centers in Shenzhen, with a maximum support of 30 million yuan; support the construction of a national enterprise technology center in Shenzhen, with the highest 15 million yuan to support.
In addition, Shenzhen will deploy and upgrade the city-level drug industry service platform, plan the city-level drug basic research and core technology research, and develop new targets, new sites, new mechanisms, new principles and other biological activities that are expected to solve major clinical needs and market needs. High-level basic research in the frontier fields of medicine will be given full funding of up to 30 million yuan; new target chemical drugs, antibody drugs, gene drugs, cell products, microbial therapy, bacterial therapy, peptide drugs, phage drugs and enzymes Engineering and other "stuck neck" core technology research and major industrial projects will be funded in stages according to 40% of the total project investment, with a maximum of no more than 300 million yuan.
The "Several Measures for Shenzhen to Promote the High-quality Development of High-end Medical Device Industry Clusters" issued this time focus on supporting high-end medical imaging, in vitro diagnosis, life monitoring and life support, tumor radiotherapy, genetic testing, optical equipment, DNA synthesizers, and intelligent rehabilitation. Instruments and equipment such as assistive devices and health management, various reagents and products required for disease screening and precise drug use analysis, high-end implantation and interventional products such as stents and valves, ventricular assist devices, intraocular lenses, orthopedic devices, degradable materials, tissue and organ induction Biomedical materials such as regeneration and repair materials, new oral materials, high-value domestic alternative consumables, surgical robots, intelligent software and other artificial intelligence information technology applications in medical equipment scenarios and other fields.
This "Several Measures for Shenzhen to Promote the High-Quality Development of Big Health Industry Clusters" focuses on supporting precision medicine, rehabilitation and elderly care, precision nutrition, modern agricultural products, medical beauty, cosmetics and other health service industries, as well as medical beauty equipment, rehabilitation Health manufacturing such as elderly care equipment, new nutritional and health care products, modern agricultural products, digital health equipment and products, and high-end cosmetics.
In terms of promoting the development of the precision medicine industry, the measures propose to create a new highland for the gene and immune cell therapy industry, support enterprises, scientific research institutions, and medical institutions to carry out industry-university-research cooperation, and support major theories, original technologies, and cutting-edge interdisciplinary basic research on gene and immune cell therapy. , striving to achieve major technological breakthroughs and original discoveries in the fields of gene editing, gene therapy, and immune cell therapy.
In addition, the Securities Times reporter was informed that Shenzhen will hold a special investment promotion meeting for Shenzhen's biomedical industry in the morning of July 28 in Pingshan District, Shenzhen.
This special investment promotion meeting is aimed at domestic and foreign leading biopharmaceutical companies, key biopharmaceutical companies in the Greater Bay Area, and upstream and downstream related companies in the biopharmaceutical industry chain.
As of 2021, the total operating income of Shenzhen's biopharmaceutical industry is 46.1 billion yuan, 7 new Class I drugs have been approved for marketing, 84 innovative drugs have entered the clinical trial stage, and 94 varieties have passed the consistency evaluation of generic drugs.
Shenzhen Nanshan High-tech Zone and Pingshan National Bio-Industry Base have initially formed two major industrial agglomeration areas. A number of innovative carriers such as the Guangdong Small Molecule New Drug Innovation Center have developed rapidly, and the agglomeration effect of industrial development has gradually become prominent.